摘要
背景:在过去二十年中,早期发现脑肿瘤的技术进步显着。 然而,在多形性成胶质细胞瘤(GBM)的治疗中没有观察到显着的改善,其是最常见的脑肿瘤加上最差的预后。 GBM的特征在于对广泛的抗肿瘤药物具有广泛的抗性。 该属性是称为多药耐药(MDR)的现象的结果,其显着限制了非侵入性替代疗法。 这种限制主要是由于ABC转运蛋白和与DNA修复相关的蛋白质如MGMT酶的活性。 由于GBM患者的死亡率高,目前的治疗缺陷,这种新型肿瘤的治疗策略至关重要。方法:本文综述了GBM治疗方案,包括使用烷化剂与MGMT抑制剂,MDR调节剂和免疫疗法。 我们将我们的书目研究集中在包含过去20年发表的体外,体内和临床阶段分析的论文中。 结果:使用烷化剂加MGMT抑制剂的几项研究已经证明了良好的效果,尽管生存率没有很大改善。 使用ABC转运蛋白的调节剂增强化疗的作用,证明它是有效的补充疗法。 免疫疗法作为GBM治疗的有针对性和个性化方法已经发生了重大进展。 结论:本评论中讨论的替代补体疗法的使用可能会增加GBM患者的生存率; 然而,需要额外的临床阶段分析和新的治疗方案的产生。
关键词: 多形性成胶质细胞瘤,烷化剂,MGMT,多重耐药性,MRP-1,免疫治疗。
Current Medicinal Chemistry
Title:Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme
Volume: 24 Issue: 25
关键词: 多形性成胶质细胞瘤,烷化剂,MGMT,多重耐药性,MRP-1,免疫治疗。
摘要: Background: In the last two decades, there have been significant technological advances in the early detection of brain tumors. However, no notable improvements have been observed in the treatment of Glioblastoma Multiforme (GBM), the most common brain neoplasm coupled with the worst prognosis. GBM is characterized by an extensive resistance to a broad spectrum of anti-tumor drugs. This property is the result of a phenomenon known as Multiple Drug Resistance (MDR), which significantly limits noninvasive alternative therapies. This limitation is primarily due to the activity of ABC transporters and proteins related with DNA repair such as the MGMT enzyme. Due to the high mortality rate in GBM patients and current treatment deficits, new therapeutic strategies for this type of neoplasm are of vital importance.
Methods: In this review, proposed treatments for GBM, including the use of alkylating agents with MGMT inhibitors, MDR modulators, and immunotherapies are discussed. We focused our bibliographic research on papers containing in vitro, in vivo, and clinical phase analysis published over the last 20 years. Results: Several studies have demonstrated good results using alkylating agents plus MGMT inhibitors, although without great improvements in survival. The use of modulators of ABC transporters enhances the effects of chemotherapy, proving it an effective complementary therapy. Immunotherapies have undergone significant developments as a directed and personalized approach for GBM treatment. Conclusion: The use of alternative complementary therapies discussed in this review could increase the survival of GBM patients; however, additional clinical phase analysis and the generation of new treatment protocols are required.Export Options
About this article
Cite this article as:
Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme, Current Medicinal Chemistry 2017; 24 (25) . https://dx.doi.org/10.2174/0929867324666170303122241
DOI https://dx.doi.org/10.2174/0929867324666170303122241 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design Sex Steroid Hormone Effects in Normal and Pathologic Conditions in Lung Physiology
Mini-Reviews in Medicinal Chemistry Refractory Cough as a Remote Manifestation of Retroperitoneal Liposarcoma
Current Cancer Therapy Reviews VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Efficacy of Pegylated Lyposomal Anthracyclines and of Intra-Arterial Carboplatin and Doxorubicin Combined with Local Hyperthermia in a Case of Malignant Endovascular Papillary Angioendothelioma
Current Drug Delivery Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry The Synthesis and Evaluation of Novel Lactate Dehydrogenase Nanobioconjugates
Current Nanoscience Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry Peripheral Biomarkers to Assess Suicide Risk
Current Psychiatry Reviews Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Recent Concise Viewpoints of Chronic Active Epstein-Barr Virus Infection
Current Pediatric Reviews Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Current Pharmaceutical Design Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Vitamin D Metabolism Genes in Asthma and Atopy
Mini-Reviews in Medicinal Chemistry Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design